Last update April 15, 2024


Likely Compatibility

Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.

Fenofibrate, a fibric acid derivative, is a lipid-regulating drug with actions on plasma lipids similar to those of bezafibrate. It decreases elevated triglyceride levels by increasing the activity of lipases that catabolize triglyceride-rich lipoproteins and decreasing LDL cholesterol levels. It also increases those of HDL cholesterol (AEMPS 2017, BGP 2015, Miller 1998). Oral administration once daily.

At the date of last update we found no published data in relation to lactation.

Its very high percentage of protein binding make its passage into milk unlikely.

Cholesterol levels are normally increased (by 40%) during pregnancy and lactation in healthy women (Lawrence 2016 p590). Milk cholesterol numbers are very stable even in hypercholesterolemic women and are not severely affected by diet or the mother's nutritional status, leading to the assumption that milk cholesterol is synthesized, at least in part, in the mammary gland (Lawrence 2016, p 289-90). Its normal concentration in breast milk varies from 30 mg/dL in colostrum to 10 - 20 mg/dL in mature milk. (Lawrence 2016 p98, 105 and 767)

It is unlikely that fibrates are capable of altering the lipid composition of milk.

If a fibrate is administered during lactation, it is advisable to choose those with a shorter half-life: Bezafibrate, Gemfibrozil.

It is advisable to follow a lipid-lowering diet and to practice regular physical activity daily, at least half an hour a day.

Cholesterol is necessary for the development of brain tissue, myelination of nerves and is the basis of many enzymes. Breastfed infants have higher plasma cholesterol levels than those fed artificial formulas and this would protect them against the consequences of hypercholesterolemia in adulthood. (Lawrence 2016 p108)

Infants fed formula substitutes ("artificial milks") do not receive cholesterol in their diet, as these products do not contain cholesterol(Lawrence 2016 p 109 and 215). The amount of cholesterol in breast milk that would remain after the hypothetical cholesterol reduction produced by the medication taken by the mother would still be much higher than that provided by the artificial formulas. (Holmsen 2017)

Discontinuing drug treatment of non-severe hyperlipidemias during the breastfeeding period is not likely to alter the long-term outcome of the disease, especially when breastfeeding can be considered therapeutic. (Lawrence 2016, p. 393)

It seems wise to advise mothers with severe hyperlipidemias to continue medication during lactation. Mothers with moderately high triglyceride and/or cholesterol levels can discontinue drug treatment during the lactation period by monitoring their low density lipoproteins (LDL) and triglyceride levels.

For considerations on the appropriateness of lipid-lowering treatment during lactation see Maternal hyperlipidemia, hypercholesterolemia, hypertriglyceridemia.

See below the information of this related product:


  • Bezafibrate (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)
  • Colesevelam Hydrochloride (Safe substance and/or breastfeeding is the best option.)
  • Colestipol Hydrochloride (Safe substance and/or breastfeeding is the best option.)
  • Colestyramine (Safe substance and/or breastfeeding is the best option.)
  • Ezetimibe (Safe substance and/or breastfeeding is the best option.)
  • Gemfibrozil (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)
  • Pravastatin Sodium (Safe substance and/or breastfeeding is the best option.)
  • Rosuvastatin Calcium (Safe substance and/or breastfeeding is the best option.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

フェノフィブラート is Fenofibrate in Japanese.

Is written in other languages:

フェノフィブラート is also known as


フェノフィブラート belongs to this group or family:


Main tradenames from several countries containing フェノフィブラート in its composition:


Variable Value Unit
Oral Bioavail. 60 - 100 %
Molecular weight 361 daltons
Protein Binding 99 %
VD 0.9 l/Kg
Tmax 2 - 6 hours
23 (19 - 27) hours


  1. AEMPS. Fenofibrato. Ficha técnica. 2017 Full text (in our servers)
  2. Holmsen ST, Bakkebø T, Seferowicz M, Retterstøl K. Statins and breastfeeding in familial hypercholesterolaemia. Tidsskr Nor Laegeforen. 2017 May 23;137(10):686-687. Abstract Full text (link to original source)
  3. Lawrence RA, Lawrence RM. Breastfeeding. A guide for the medical profession. Eighth Edition. Philadelphia: Elsevier; 2016
  4. BGP. Fenofibrate. Drug Summary. 2015 Full text (in our servers)
  5. Miller DB, Spence JD. Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet. 1998 Abstract

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at

e-lactancia is a resource recommended by El Parto Es Nuestro of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM